XML 83 R58.htm IDEA: XBRL DOCUMENT v3.24.1

Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)	1 Months Ended			3 Months Ended	12 Months Ended
	Jun. 30, 2023 USD ($)	Sep. 30, 2021 USD ($)	May 31, 2021 USD ($) licenseAgreement	Mar. 31, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2017 USD ($)
Licensing Agreement [Line Items]
Research and development expense				$ 41,128,000	$ 232,366,000	$ 248,149,000	$ 195,958,000
Loss on equity method investment					7,549,000	12,107,000	803,000
3M IPC and Access to Advanced Health Institute License Agreement | License Agreement Terms | 2022
Licensing Agreement [Line Items]
Periodic license payments	$ 2,250,000
Annual minimum licensing payment					1,000,000
License maintenance fees								$ 1,750,000
Research and development expense					2,000,000	1,000,000	500,000
Access to Advanced Health Institute (AAHI)
Licensing Agreement [Line Items]
Number of license agreements | licenseAgreement			2
Non-refundable upfront cash payments			$ 2,000,000
Milestone payment, aggregate maximum			$ 2,500,000
Milestone fees					0	0
Access to Advanced Health Institute (AAHI) | License Agreement Terms
Licensing Agreement [Line Items]
Non-refundable upfront cash payments		$ 1,500,000
Milestone payment, aggregate maximum		$ 4,000,000
Termination fee					10,000,000
Access to Advanced Health Institute (AAHI) | License Agreement Terms | 2022
Licensing Agreement [Line Items]
License maintenance fees								$ 3,000,000
Research and development expense					4,500,000	1,800,000	$ 1,500,000
Access to Advanced Health Institute (AAHI) | License Agreement Terms | 2023 through 2030
Licensing Agreement [Line Items]
License maintenance fees					5,500,000
Access to Advanced Health Institute (AAHI) | Sponsored Research Agreement
Licensing Agreement [Line Items]
Research and development expense					1,200,000
License payable					500,000
Loss on equity method investment						$ 3,700,000
Access to Advanced Health Institute (AAHI) | Sponsored Research Agreement | Minimum
Licensing Agreement [Line Items]
Annual payment for support of research activities					$ 2,000,000
Viracta | License Agreement
Licensing Agreement [Line Items]
Milestone payment, aggregate maximum									$ 100,000,000
Viracta | License Agreement | Minimum
Licensing Agreement [Line Items]
Milestone payment, amount									10,000,000
Viracta | License Agreement | Maximum
Licensing Agreement [Line Items]
Milestone payment, amount									$ 25,000,000

X

- Definition

Collaboration Agreements, Annual Minimum Licensing Payment

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Annual payment for support of research activities.

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaboration Agreements, License Maintenance Fees

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsLicenseMaintenanceFees
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Collaboration Agreements, License Maintenance Fees Payable

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Collaboration Agreements, Milestone Fees

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsMilestoneFees
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaboration Agreements, Milestone Payment, Aggregate Maximum

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Collaboration Agreements, Milestone Payment, Amount

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsMilestonePaymentAmount
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Nonrefundable upfront payment.

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsNonrefundableUpfrontPayment
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaboration Agreements, Number Of License Agreements

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsNumberOfLicenseAgreements
Namespace Prefix:	ibrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaboration Agreements, Periodic License Payments

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsPeriodicLicensePayments
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaboration Agreements, Termination Fee

+ References

No definition available.

+ Details

Name:	ibrx_CollaborationAgreementsTerminationFee
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Licensing agreement.

+ References

No definition available.

+ Details

Name:	ibrx_LicensingAgreementLineItems
Namespace Prefix:	ibrx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of income (loss) for proportionate share of equity method investee's income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481664/323-10-45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Name:	us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibrx_A3MIPCAndAAHIAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis=ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibrx_AAHIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis=ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_SponsoredResearchAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibrx_ViractaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: